EE200100140A - Botuliintoksiini stabiilsed vedelad formulatsioonid - Google Patents

Botuliintoksiini stabiilsed vedelad formulatsioonid

Info

Publication number: EE200100140A
Authority: EE; Estonia
Prior art keywords: botulinum toxin; liquid formulations; stable liquid; stable; formulations
Prior art date: 1998-09-11

Application number

EEP200100140A

Other languages

English (en)

Estonian (et)

Inventor

Moyer Elizabeth

Hirtzer Pamela

Original Assignee

Elan Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-11

Filing date

1999-09-09

Publication date

2002-06-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-09 Application filed by Elan Pharmaceuticals, Inc. filed Critical Elan Pharmaceuticals, Inc.

2002-06-17 Publication of EE200100140A publication Critical patent/EE200100140A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Birds (AREA)
Psychology (AREA)
Rheumatology (AREA)
Gerontology & Geriatric Medicine (AREA)
Pregnancy & Childbirth (AREA)
Oil, Petroleum & Natural Gas (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)

EEP200100140A 1998-09-11 1999-09-09 Botuliintoksiini stabiilsed vedelad formulatsioonid EE200100140A (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US9987098P	1998-09-11	1998-09-11
PCT/US1999/020912 WO2000015245A2 (fr)	1998-09-11	1999-09-09	Formulations liquides stables de la toxine de botulinum

Publications (1)

Publication Number	Publication Date
EE200100140A true EE200100140A (et)	2002-06-17

Family

ID=22277018

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100140A EE200100140A (et)	1998-09-11	1999-09-09	Botuliintoksiini stabiilsed vedelad formulatsioonid

Country Status (40)

Country	Link
US (2)	US7211261B1 (fr)
EP (1)	EP1112082B2 (fr)
JP (4)	JP4557426B2 (fr)
KR (1)	KR100699756B1 (fr)
CN (1)	CN100438905C (fr)
AP (1)	AP1591A (fr)
AR (1)	AR022671A1 (fr)
AT (1)	ATE221386T1 (fr)
AU (1)	AU755556C (fr)
BG (1)	BG65555B1 (fr)
BR (1)	BR9913585A (fr)
CA (1)	CA2342243C (fr)
CO (1)	CO5170497A1 (fr)
CU (1)	CU23251A3 (fr)
DE (1)	DE69902396T3 (fr)
DK (1)	DK1112082T4 (fr)
EA (1)	EA003367B1 (fr)
EE (1)	EE200100140A (fr)
ES (1)	ES2181473T5 (fr)
GE (1)	GEP20032946B (fr)
HR (1)	HRP20010259B1 (fr)
HU (1)	HUP0103638A3 (fr)
ID (1)	ID28824A (fr)
IL (2)	IL141564A0 (fr)
IS (1)	IS2381B (fr)
LT (1)	LT4959B (fr)
LV (1)	LV12684B (fr)
NO (1)	NO328898B1 (fr)
NZ (1)	NZ509349A (fr)
PL (1)	PL200926B1 (fr)
PT (1)	PT1112082E (fr)
RS (1)	RS50344B (fr)
SA (1)	SA99200566B1 (fr)
SI (2)	SI20566B (fr)
SK (1)	SK286919B6 (fr)
TR (1)	TR200100728T2 (fr)
TW (1)	TW574036B (fr)
UA (1)	UA72477C2 (fr)
WO (1)	WO2000015245A2 (fr)
ZA (1)	ZA200101709B (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0758900T3 (da) *	1994-05-09	2002-07-29	William J Binder	Botulinumtoksin til reduktion af migræne-hovedpinesmerter
US20120238504A1 (en) *	1998-09-11	2012-09-20	Solstice Neurosciences, Llc	Stable Formulations of Botulinum Toxin in Hydrogels
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
DE19925739A1 (de) *	1999-06-07	2000-12-21	Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh	Therapeutikum mit einem Botulinum-Neurotoxin
US7838008B2 (en)	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating diverse cancers
US7838007B2 (en)	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating mammary gland disorders
US8632785B2 (en) *	2000-02-08	2014-01-21	Allergan, Inc.	Clostridial toxin pharmaceutical composition containing a gelatin fragment
US7780967B2 (en)	2000-02-08	2010-08-24	Allergan, Inc.	Reduced toxicity Clostridial toxin pharmaceutical compositions
US20030118598A1 (en)	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
NZ520201A (en) *	2000-02-08	2004-04-30	Allergan Inc	Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US20060269575A1 (en) *	2000-02-08	2006-11-30	Allergan, Inc.	Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US6821520B2 (en)	2000-02-15	2004-11-23	Allergan, Inc.	Clostridial toxin therapy for Hashimoto's thyroiditis
ITUD20010002A1 (it) *	2001-01-05	2002-07-05	Univ Degli Studi Udine	Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
CA2369810C (fr) *	2002-01-30	2007-08-07	1474791 Ontario Limited	Methode de traitement de la douleur
US6688311B2 (en)	2002-03-14	2004-02-10	Allergan, Inc.	Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en)	2002-03-14	2006-11-28	Allergan, Inc.	Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
WO2003082315A1 (fr) *	2002-03-29	2003-10-09	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Remede contre l'hypermyotonie
US7691394B2 (en)	2002-05-28	2010-04-06	Botulinum Toxin Research Associates, Inc.	High-potency botulinum toxin formulations
US20040009180A1 (en) *	2002-07-11	2004-01-15	Allergan, Inc.	Transdermal botulinum toxin compositions
AU2003295769A1 (en)	2002-11-21	2004-06-18	Ira Sanders	Treatment of mammalian reaction to ige interactions
MXPA05006690A (es) *	2002-12-20	2006-02-17	Botulinum Toxin Res Ass Inc	Composiciones farmaceuticas de toxina botulinica mejoradas.
US8071550B2 (en)	2003-03-03	2011-12-06	Allergan, Inc.	Methods for treating uterine disorders
EP1599220B1 (fr) *	2003-03-06	2013-07-17	Botulinum Toxin Research Associates, Inc.	Selection de patients a sensibilite accrue a la toxine botulique
ZA200506715B (en) *	2003-03-06	2007-05-30	Botulinum Toxin Res Ass Inc	Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US6838434B2 (en) *	2003-05-02	2005-01-04	Allergan, Inc.	Methods for treating sinus headache
US7220422B2 (en) *	2003-05-20	2007-05-22	Allergan, Inc.	Methods and compositions for treating eye disorders
US8617572B2 (en)	2003-10-29	2013-12-31	Allergan, Inc.	Botulinum toxin treatments of depression
US8734810B2 (en)	2003-10-29	2014-05-27	Allergan, Inc.	Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en)	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
US8609113B2 (en)	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
SG150570A1 (en)	2004-03-03	2009-03-30	Revance Therapeutics Inc	Compositions and methods for topical diagnostic and therapeutic transport
AU2005218665A1 (en) *	2004-03-03	2005-09-15	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en)	2004-03-03	2015-12-15	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005274822B2 (en)	2004-07-26	2008-10-30	Merz Pharma Gmbh & Co. Kgaa	Therapeutic composition with a botulinum neurotoxin
US7179474B2 (en)	2004-09-03	2007-02-20	Allergan, Inc.	Methods for treating a buttock deformity
US7429386B2 (en)	2004-09-03	2008-09-30	Allergan, Inc.	Stretch mark treatment
US8192979B2 (en)	2005-01-03	2012-06-05	Botulinum Toxin Research Associates, Inc.	Compositions, methods and devices for preparing less painful Botulinum toxin formulations
SG160357A1 (en)	2005-03-03	2010-04-29	Revance Therapeutics Inc	Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7419675B2 (en)	2005-05-26	2008-09-02	Allergan, Inc.	Method for treating peritoneal adhesions
US8323666B2 (en)	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
US8137677B2 (en)	2005-10-06	2012-03-20	Allergan, Inc.	Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
DE102006019447A1 (de) *	2006-04-24	2007-10-25	Dressler, Dirk, Dr.	Markierung von Botulinum Toxin
AR061669A1 (es) *	2006-06-29	2008-09-10	Merz Pharma Gmbh & Co Kgaa	Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en)	2006-06-29	2020-10-06	Merz Pharma Gmbh & Co. Kgaa	High frequency application of botulinum toxin therapy
EP2048156A1 (fr) *	2007-10-12	2009-04-15	Merz Pharma GmbH & Co.KGaA	Procédé pour fournir un relaxant musculaire à température stable sur la base d'un composant neurotoxique de toxine botulique
CN101720331A (zh) *	2007-06-01	2010-06-02	德国麦氏大药厂	基于肉毒毒素的神经毒成分供应温度-稳定性肌肉松弛剂的方法
US9107815B2 (en)	2008-02-22	2015-08-18	Allergan, Inc.	Sustained release poloxamer containing pharmaceutical compositions
US20100034854A1 (en) *	2008-08-05	2010-02-11	Solstice Neurosciences, Inc.	Compositions of activated botulinum holotoxin type B (150 KD)
WO2010016895A1 (fr) *	2008-08-05	2010-02-11	Solstice Neurosciences, Inc.	Compositions de toxine botulinique activée de type b
US20100112005A1 (en) *	2008-11-03	2010-05-06	Solstice Neurosciences, Inc.	Compositions of activated botulinum toxin type B
WO2010051038A1 (fr) *	2008-11-03	2010-05-06	Solstice Neurosciences, Inc.	Compositions d’holotoxine botulinique activée de type b (150 kd)
US20100124559A1 (en) *	2008-11-20	2010-05-20	Allergan, Inc.	Early Treatment and Prevention of Increased Muscle Tonicity
EP2364168A1 (fr)	2008-12-04	2011-09-14	Botulinum Toxin Research Associates, Inc.	Formulation de toxine botulique à durée de vie prolongée pour utilisation chez un humain ou un mammifère
BRPI0923731B1 (pt)	2008-12-31	2024-02-06	Revance Therapeutics, Inc	Composições para uso em um método não-terapêutico de administração de toxina botulínica, seus usos e método de preparação
EP2248518B1 (fr) *	2009-04-17	2013-01-16	Merz Pharma GmbH & Co. KGaA	Formulation pour stabiliser des protéines, des peptides et ses mélanges.
BRPI1015938A2 (pt)	2009-06-25	2016-09-27	Revance Therapeutics Inc	formulações da toxina botulínica livre de albumina
MX352265B (es)	2009-07-02	2017-11-16	Merz Pharma Gmbh & Co Kgaa	Neurotoxinas que exhiben actividad biologica acortada.
ES2688065T5 (es) *	2009-10-21	2024-10-04	Revance Therapeutics Inc	Métodos y sistemas para purificar la neurotoxina botulínica no complejada
RU2440812C1 (ru) *	2010-05-27	2012-01-27	ФГУ "НКЦ Оториноларингологии" Федерального медико-биологического агентства России	Способ лечения гипотонусных дисфоний
SG10201804552WA (en) *	2011-01-24	2018-07-30	Anterios Inc	Nanoparticle compositions, formulations thereof, and uses therefor
RU2646110C2 (ru)	2011-11-09	2018-03-01	Мерц Фарма Гмбх Унд Ко. Кгаа	Нейротоксины, проявляющие укороченную биологическую активность
US9393291B2 (en)	2012-04-12	2016-07-19	Botulinum Toxin Research Associates, Inc.	Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014066916A2 (fr)	2012-10-28	2014-05-01	Revance Therapeutics, Inc.	Compositions et procédés pour le traitement sûr de la rhinite
RU2535115C1 (ru) *	2013-05-15	2014-12-10	Бости Трейдинг Лтд	Фармацевтический состав, содержащий нейротоксин ботулина
US9901627B2 (en)	2014-07-18	2018-02-27	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en)	2014-07-18	2022-11-01	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR20170093780A (ko)	2014-09-02	2017-08-16	아메리칸 실버, 엘엘씨	보툴리눔 톡신 및 콜로이드 은 입자
AR103243A1 (es)	2014-12-23	2017-04-26	Merz Pharma Gmbh & Co Kgaa	Recipiente precargado con toxina botulínica
RU2722290C2 (ru) *	2015-02-03	2020-05-28	Мерц Фарма Гмбх Унд Ко. Кгаа	Контейнер, предварительно заполненный ботулиновым токсином
SI3679946T1 (sl) *	2016-05-27	2022-04-29	Ipsen Biopharma Limited	Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom
WO2018038301A1 (fr) *	2016-08-26	2018-03-01	Hugel Inc.	Formulation liquide stabilisée de toxine botulique et procédé pour sa préparation
TW202247855A (zh)	2016-09-13	2022-12-16	美商愛力根公司	非蛋白梭菌毒素組成物
CN117731591A (zh)	2016-11-21	2024-03-22	艾里奥治疗公司	大试剂的透皮递送
KR101744900B1 (ko)	2017-01-20	2017-06-08	주식회사 대웅	보툴리눔 독소를 포함하는 안정한 액상 조성물
RU2019141383A (ru) *	2017-05-18	2021-06-18	Реванс Терапьютикс, Инк. (Revance Therapeutics, Inc.)	Способы лечения цервикальной дистонии
KR102063475B1 (ko)	2018-02-22	2020-01-09	주식회사 에이비바이오	보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
GB201815844D0 (en)	2018-09-28	2018-11-14	Ipsen Biopharm Ltd	Therapeutic & comestic uses of botulinum neurotoxin serotype e
EP3863589B1 (fr)	2018-10-08	2025-12-03	Merz Pharma GmbH & Co. KGaA	Flacon pré-rempli de toxine botulique

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3522247A (en) *	1967-11-07	1970-07-28	Pfizer & Co C	2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators
US4932936A (en)	1988-01-29	1990-06-12	Regents Of The University Of Minnesota	Method and device for pharmacological control of spasticity
US5053005A (en)	1989-04-21	1991-10-01	Gary E. Borodic	Chemomodulation of curvature of the juvenile spine
US5919665A (en) *	1989-10-31	1999-07-06	Ophidian Pharmaceuticals, Inc.	Vaccine for clostridium botulinum neurotoxin
US5183462A (en) *	1990-08-21	1993-02-02	Associated Synapse Biologics	Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en)	1991-09-24	1991-11-06	Graham Herbert K	Method and compositions for the treatment of cerebral palsy
EP0654040A1 (fr)	1992-06-23	1995-05-24	Interactive Biologics Associates	Composition pharmaceutique contenant un complexe de botulinum b
JPH06192118A (ja) *	1992-09-28	1994-07-12	Wisconsin Alumni Res Found	ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
ES2194025T3 (es)	1993-06-10	2003-11-16	Allergan Inc	Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
AU689115B2 (en)	1993-06-10	1998-03-26	Allergan, Inc.	Treatment of neuromuscular disorders and conditions with different botulinum serotype
GB9315306D0 (en)	1993-07-23	1993-09-08	Smithkline Beecham Corp	Methods
US5437291A (en) *	1993-08-26	1995-08-01	Univ Johns Hopkins	Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
DE69427869T2 (de)	1993-12-28	2002-04-11	Allergan Sales Inc	Botulinumtoxine zur behandlung von hyperhydrosis
US6974578B1 (en) *	1993-12-28	2005-12-13	Allergan, Inc.	Method for treating secretions and glands using botulinum toxin
US5766605A (en)	1994-04-15	1998-06-16	Mount Sinai School Of Medicine Of The City University Of New York	Treatment of autonomic nerve dysfunction with botulinum toxin
DK0758900T3 (da)	1994-05-09	2002-07-29	William J Binder	Botulinumtoksin til reduktion af migræne-hovedpinesmerter
WO1996005222A1 (fr) *	1994-08-08	1996-02-22	Wisconsin Alumni Research Foundation	Procede de purification et compositions pharmaceutiques contenant la neurotoxine botulinique de type g
US5756468A (en) *	1994-10-13	1998-05-26	Wisconsin Alumni Research Foundation	Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en)	1994-10-13	1996-04-30	Wisconsin Alumni Research Foundation	Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5562899A (en)	1995-02-28	1996-10-08	Gerber; Allen	Medical prevention of lacerations to the vagina and perineum
US6136551A (en) *	1995-04-24	2000-10-24	Allergan, Inc.	Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
EP0773788B1 (fr) *	1995-06-06	2003-05-07	L. Bruce Pearce	Compositions et procedes de chimiodenervation ameliores, recourant aux neurotoxines
US5721215A (en)	1996-03-20	1998-02-24	Allergan	Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) *	1996-07-08	2004-03-02	University Of Massachusetts	Proteins within the type E botulinum neurotoxin complex
CN1057430C (zh) *	1996-10-09	2000-10-18	崔生发	一种生物化学杀鼠剂
TW574036B (en) *	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
US6146902A (en) *	1998-12-29	2000-11-14	Aventis Pasteur, Inc.	Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6113915A (en)	1999-10-12	2000-09-05	Allergan Sales, Inc.	Methods for treating pain
US6139845A (en)	1999-12-07	2000-10-31	Allergan Sales, Inc.	Method for treating cancer with a neurotoxin
US20030118598A1 (en) *	2000-02-08	2003-06-26	Allergan, Inc.	Clostridial toxin pharmaceutical compositions
NZ520201A (en) *	2000-02-08	2004-04-30	Allergan Inc	Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US6358513B1 (en)	2000-02-15	2002-03-19	Allergan Sales, Inc.	Method for treating Hashimoto's thyroiditis
US6464986B1 (en) *	2000-04-14	2002-10-15	Allegan Sales, Inc.	Method for treating pain by peripheral administration of a neurotoxin
US20080096238A1 (en) *	2004-03-30	2008-04-24	Alcon, Inc.	High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
CN1946738A (zh) *	2005-03-03	2007-04-11	阿勒根公司	用于纯化肉毒毒素的不含动物产物的系统和方法
US8052979B2 (en)	2005-03-15	2011-11-08	Allergan, Inc.	Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7691587B2 (en) *	2006-06-01	2010-04-06	Allergan, Inc.	Determining and reducing immunoresistance to a botulinum toxin therapy using botulinum toxin B peptides

1999
- 1999-08-31 TW TW88114941A patent/TW574036B/zh active
- 1999-09-07 SA SA99200566A patent/SA99200566B1/ar unknown
- 1999-09-09 WO PCT/US1999/020912 patent/WO2000015245A2/fr not_active Ceased
- 1999-09-09 AU AU58214/99A patent/AU755556C/en not_active Ceased
- 1999-09-09 GE GEAP19995844A patent/GEP20032946B/en unknown
- 1999-09-09 US US09/393,590 patent/US7211261B1/en not_active Expired - Lifetime
- 1999-09-09 CN CNB998107395A patent/CN100438905C/zh not_active Expired - Fee Related
- 1999-09-09 EE EEP200100140A patent/EE200100140A/xx unknown
- 1999-09-09 IL IL14156499A patent/IL141564A0/xx unknown
- 1999-09-09 CO CO99057166A patent/CO5170497A1/es not_active Application Discontinuation
- 1999-09-09 DE DE69902396T patent/DE69902396T3/de not_active Expired - Lifetime
- 1999-09-09 ES ES99945649T patent/ES2181473T5/es not_active Expired - Lifetime
- 1999-09-09 CA CA2342243A patent/CA2342243C/fr not_active Expired - Lifetime
- 1999-09-09 ID IDW20010592A patent/ID28824A/id unknown
- 1999-09-09 SK SK313-2001A patent/SK286919B6/sk not_active IP Right Cessation
- 1999-09-09 EP EP99945649A patent/EP1112082B2/fr not_active Expired - Lifetime
- 1999-09-09 NZ NZ509349A patent/NZ509349A/en not_active IP Right Cessation
- 1999-09-09 PT PT99945649T patent/PT1112082E/pt unknown
- 1999-09-09 RS YUP-190/01A patent/RS50344B/sr unknown
- 1999-09-09 AT AT99945649T patent/ATE221386T1/de active
- 1999-09-09 SI SI9920081A patent/SI20566B/sl not_active IP Right Cessation
- 1999-09-09 AP APAP/P/2001/002108A patent/AP1591A/en active
- 1999-09-09 KR KR1020017003032A patent/KR100699756B1/ko not_active Expired - Fee Related
- 1999-09-09 EA EA200100337A patent/EA003367B1/ru not_active IP Right Cessation
- 1999-09-09 PL PL347069A patent/PL200926B1/pl not_active IP Right Cessation
- 1999-09-09 HU HU0103638A patent/HUP0103638A3/hu unknown
- 1999-09-09 SI SI9930126T patent/SI1112082T1/xx unknown
- 1999-09-09 DK DK99945649.4T patent/DK1112082T4/da active
- 1999-09-09 TR TR2001/00728T patent/TR200100728T2/xx unknown
- 1999-09-09 HR HR20010259A patent/HRP20010259B1/xx not_active IP Right Cessation
- 1999-09-09 JP JP2000569829A patent/JP4557426B2/ja not_active Expired - Lifetime
- 1999-09-09 BR BR9913585-0A patent/BR9913585A/pt not_active Application Discontinuation
- 1999-09-09 AR ARP990104540A patent/AR022671A1/es unknown
- 1999-09-09 UA UA2001042366A patent/UA72477C2/uk unknown
2001
- 2001-01-31 IS IS5836A patent/IS2381B/is unknown
- 2001-02-21 IL IL141564A patent/IL141564A/en not_active IP Right Cessation
- 2001-02-28 ZA ZA200101709A patent/ZA200101709B/en unknown
- 2001-03-09 NO NO20011207A patent/NO328898B1/no not_active IP Right Cessation
- 2001-03-12 CU CU20010063A patent/CU23251A3/es not_active IP Right Cessation
- 2001-04-10 LV LV010056A patent/LV12684B/xx unknown
- 2001-04-10 BG BG105435A patent/BG65555B1/bg unknown
- 2001-04-10 LT LT2001041A patent/LT4959B/lt not_active IP Right Cessation
2007
- 2007-03-08 US US11/683,628 patent/US8173138B2/en not_active Expired - Fee Related
- 2007-03-27 JP JP2007083103A patent/JP2007169301A/ja not_active Withdrawn
2010
- 2010-02-26 JP JP2010043514A patent/JP5270594B2/ja not_active Expired - Lifetime
2013
- 2013-02-28 JP JP2013039884A patent/JP2013144691A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU755556C (en)	2005-12-15
CN1316906A (zh)	2001-10-10
SI1112082T1 (en)	2002-12-31
YU19001A (sh)	2005-06-10
UA72477C2 (uk)	2005-03-15
PL347069A1 (en)	2002-03-11
US7211261B1 (en)	2007-05-01
JP2010138186A (ja)	2010-06-24
CA2342243C (fr)	2014-01-14
HRP20010259B1 (hr)	2007-11-30
DK1112082T4 (da)	2010-05-31
HUP0103638A3 (en)	2004-06-28
SI20566B (sl)	2008-08-31
EA003367B1 (ru)	2003-04-24
AU5821499A (en)	2000-04-03
DE69902396T3 (de)	2010-09-30
ES2181473T5 (es)	2010-07-05
CU23251A3 (es)	2007-12-17
KR100699756B1 (ko)	2007-03-27
AU755556B2 (en)	2002-12-12
US8173138B2 (en)	2012-05-08
DK1112082T3 (da)	2002-11-25
RS50344B (sr)	2009-11-10
PT1112082E (pt)	2002-12-31
PL200926B1 (pl)	2009-02-27
EA200100337A1 (ru)	2001-10-22
NO20011207L (no)	2001-05-09
ATE221386T1 (de)	2002-08-15
EP1112082B1 (fr)	2002-07-31
CN100438905C (zh)	2008-12-03
JP4557426B2 (ja)	2010-10-06
NO328898B1 (no)	2010-06-07
ES2181473T3 (es)	2003-02-16
HUP0103638A2 (hu)	2002-01-28
LT2001041A (en)	2002-06-25
ID28824A (id)	2001-07-05
AP2001002108A0 (en)	2001-03-31
US20070148189A1 (en)	2007-06-28
SA99200566B1 (ar)	2006-09-20
HK1040927A1 (zh)	2002-06-28
BG65555B1 (bg)	2008-12-30
IL141564A (en)	2009-08-03
EP1112082A2 (fr)	2001-07-04
WO2000015245A2 (fr)	2000-03-23
KR20010086388A (ko)	2001-09-10
IS5836A (is)	2001-01-31
LT4959B (lt)	2002-10-25
WO2000015245A3 (fr)	2000-06-08
CO5170497A1 (es)	2002-06-27
DE69902396D1 (de)	2002-09-05
ZA200101709B (en)	2002-11-28
AR022671A1 (es)	2002-09-04
NZ509349A (en)	2003-08-29
BR9913585A (pt)	2001-06-05
SK286919B6 (sk)	2009-07-06
JP2013144691A (ja)	2013-07-25
JP2002524527A (ja)	2002-08-06
EP1112082B2 (fr)	2010-03-17
TW574036B (en)	2004-02-01
TR200100728T2 (tr)	2001-08-21
DE69902396T2 (de)	2003-03-20
CA2342243A1 (fr)	2000-03-23
IL141564A0 (en)	2002-03-10
LV12684A (en)	2001-07-20
NO20011207D0 (no)	2001-03-09
LV12684B (lv)	2001-10-20
SK3132001A3 (en)	2001-10-08
SI20566A (sl)	2001-12-31
GEP20032946B (en)	2003-04-25
HRP20010259A2 (en)	2005-02-28
AP1591A (en)	2006-03-20
BG105435A (en)	2001-12-29
IS2381B (is)	2008-07-15
JP5270594B2 (ja)	2013-08-21
JP2007169301A (ja)	2007-07-05

Publication	Publication Date	Title
EE200100140A (et)	2002-06-17	Botuliintoksiini stabiilsed vedelad formulatsioonid
DK0853945T3 (da)	2003-08-04	Flydende gonadotropinholdige formuleringer
IS2325B (is)	2007-12-15	Örgerðar samsetningar epleróns
NO20004721D0 (no)	2000-09-21	Bruseformuleringer
PT1109558E (pt)	2002-10-31	Formulacoes de ranolazina de libertacao controlada
FI952610L (fi)	1995-07-13	Stabiloituja, nestemäisiä entsyymikoostumuksia
ID27847A (id)	2001-04-26	Komposisi kosmetik
DE69707887D1 (de)	2001-12-06	Antitranspirant/deodorant flüssige zusammensetzung
DK1109449T3 (da)	2003-03-03	Mikrokapselformuleringer
ITTO970952A0 (it)	1997-10-31	Composizione liquida di pulizia
ATE263487T1 (de)	2004-04-15	Flüssige formulierungen
DE59910836D1 (de)	2004-11-18	Dermal applizierbare wasserhaltige formulierungen von parasitiziden
ATE357237T1 (de)	2007-04-15	Formulierungen enthaltend cefuroxim-axetil
ATE232683T1 (de)	2003-03-15	Mikrokapsel-formulierungen
NO20005722D0 (no)	2000-11-13	Brusetilberedninger
EE9900113A (et)	1999-10-15	Vedelad alendronaatpreparaadid
ATE264616T1 (de)	2004-05-15	Flüssigformulierung
IT1288113B1 (it)	1998-09-10	Composizioni farmaceutiche effervescenti contenenti sobrerolo
IT1284509B1 (it)	1998-05-21	Composizioni farmaceutiche effervescenti contenenti metansolfoanilidi
SE9802197D0 (sv)	1998-06-18	Formulations of busulphan

Legal Events

Date	Code	Title	Description
2008-08-15	GB1A	Change in the ownership or in the address of the owner